Cellectar Biosciences, Inc.

Clinical trials sponsored by Cellectar Biosciences, Inc., explained in plain language.

Cellectar Biosciences, Inc. CLRB NASDAQ

A biopharmaceutical company developing phospholipid-drug conjugates for cancer treatment.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet recruiting 1 Not yet finished but already full! 3

New hope for Hard-to-Treat breast cancer: experimental drug CLR 125 enters human testing

Disease control Recruiting now

This early-phase study is testing an experimental drug called CLR 125 in 60 people with advanced triple-negative breast cancer that has not responded to prior treatments. The main goals are to find the safest and most effective dose and to understand what side effects occur. Part…

Phase 1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control

Last updated Jun 27, 2026 13:01 UTC

Cellectar Biosciences, Inc.

New hope for Hard-to-Treat breast cancer: experimental drug CLR 125 enters human testing